Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus.

IF 4.8 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-10-02 DOI:10.1080/14760584.2025.2562201

Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W Law, Diana Mendes

{"title":"Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus.","authors":"Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W Law, Diana Mendes","doi":"10.1080/14760584.2025.2562201","DOIUrl":null,"url":null,"abstract":"Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.Research design and methods: A cohort model was developed to evaluate cost-effectiveness of strategies preventing RSV-LRTI in infants. Using the model, we calculated the economically justifiable price (EJP) of maternal RSVpreF vaccination (MV) versus no intervention and then evaluated the cost-effectiveness of MV (cost/dose assumed at EJP) with complementary use of monoclonal antibody nirsevimab for unprotected infants (MV+N) versus nirsevimab alone (NA) to prevent RSV-LRTI. Nirsevimab published price was $260.00; costs/prices reported in 2023 US$.Results: NA yielded 20,247 cases (hospital: 3,773, emergency ward: 16,474) and $57.2 million (M) in total costs (medical: $6.3 M, intervention: $48.7 M, indirect: $2.2 M). MV+N yielded 23,906 cases (hospital: 3,137, emergency ward: 20,769) and $28.7 M in costs (medical: $4.8 M, intervention: $21.7 M [RSVpreF assumed $75.77/dose; nirsevimab procured $260.00/dose], indirect: $2.2 M). With costs lower by $28.4 M and increased quality-adjusted life-years, MV+N would be cost-saving versus NA.Conclusions: RSVpreF vaccination among pregnant women along with nirsevimab for unprotected infants in Chile would be the most efficient use of resources, yielding substantial cost savings compared to use of nirsevimab alone.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"904-913"},"PeriodicalIF":4.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2562201","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.

Research design and methods: A cohort model was developed to evaluate cost-effectiveness of strategies preventing RSV-LRTI in infants. Using the model, we calculated the economically justifiable price (EJP) of maternal RSVpreF vaccination (MV) versus no intervention and then evaluated the cost-effectiveness of MV (cost/dose assumed at EJP) with complementary use of monoclonal antibody nirsevimab for unprotected infants (MV+N) versus nirsevimab alone (NA) to prevent RSV-LRTI. Nirsevimab published price was $260.00; costs/prices reported in 2023 US$.

Results: NA yielded 20,247 cases (hospital: 3,773, emergency ward: 16,474) and $57.2 million (M) in total costs (medical: $6.3 M, intervention: $48.7 M, indirect: $2.2 M). MV+N yielded 23,906 cases (hospital: 3,137, emergency ward: 20,769) and $28.7 M in costs (medical: $4.8 M, intervention: $21.7 M [RSVpreF assumed $75.77/dose; nirsevimab procured $260.00/dose], indirect: $2.2 M). With costs lower by $28.4 M and increased quality-adjusted life-years, MV+N would be cost-saving versus NA.

Conclusions: RSVpreF vaccination among pregnant women along with nirsevimab for unprotected infants in Chile would be the most efficient use of resources, yielding substantial cost savings compared to use of nirsevimab alone.

查看原文本刊更多论文

使用预防干预措施保护智利婴儿免受呼吸道合胞体病毒感染战略的成本效益。

背景：呼吸道合胞病毒（RSV）是智利婴儿下呼吸道疾病（LRTI; RSV-LRTI）的主要原因；年幼婴儿和早产婴儿面临的风险最大。研究设计和方法：建立了一个队列模型来评估预防婴儿RSV-LRTI策略的成本效益。使用该模型，我们计算了母亲接种RSVpreF疫苗（MV）与不干预的经济合理价格（EJP），然后评估了MV （EJP时假定的成本/剂量）与无保护婴儿补充使用单克隆抗体nirsevimab （MV+N）相比，单独使用nirsevimab （NA）预防RSV-LRTI的成本效益。Nirsevimab公布价格为260.00美元；2023年报告成本/价格为美元。结果：NA产生了20,247例病例（医院：3,773例，急诊病房：16474例），总费用为5,720万美元(M)（医疗：630万美元，干预：4870万美元，间接：220万美元）。MV+N产生了23,906例病例（医院：3,137例，急诊病房：20769例），成本为2870万美元（医疗：480万美元，干预：2170万美元[RSVpreF假设75.77美元/剂；nirsevimab采购260.00美元/剂]，间接：220万美元）。由于成本降低了2840万美元，并增加了质量调整寿命年，MV+N将比NA节省成本。结论：在智利，孕妇接种RSVpreF疫苗的同时，为未受保护的婴儿接种尼瑟维单抗将是最有效的资源利用，与单独使用尼瑟维单抗相比，可节省大量成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.